SCHEMBL24253948

SCHEMBL24253948

O=C1CCCC2(CCN(c3cc(C(F)(F)F)nc(CO)n3)CC2)N1c1ccc(F)c(F)c1

nearest known ligand 0.34

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 3/20 0.34
HCRTR2 O43614 3/20 0.34
KCNH2 Q12809 1/20 0.34
LTC4S Q16873 1/20 0.34
SLC6A2 P23975 2/20 0.33
SLC6A3 Q01959 2/20 0.33
DRD2 P14416 12/20 0.33
DRD3 P35462 12/20 0.33
FFAR4 Q5NUL3 1/20 0.33
HTR1A P08908 1/20 0.32
ADRA1D P25100 1/20 0.32
ADRA1A P35348 1/20 0.32
ADRA1B P35368 1/20 0.32
TRPV1 Q8NER1 1/20 0.31
SLC6A4 P31645 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30423952 1.00 HCRTR1 (0.34) HCRTR1HCRTR2KCNH2LTC4SSLC6A2
SCHEMBL24253747 0.93 HCRTR1 (0.35) HCRTR1HCRTR2KCNH2LTC4SDRD2
SCHEMBL24253946 0.86 KDM4E (0.32) HCRTR1HCRTR2KCNH2LTC4SSLC6A2
SCHEMBL30006991 0.86 KDM4E (0.32) HCRTR1HCRTR2KCNH2LTC4SSLC6A2
SCHEMBL24253952 0.86 MAPT (0.34) HCRTR1HCRTR2KCNH2LTC4SSLC6A2
SCHEMBL30423848 0.86 HCRTR1 (0.31) HCRTR1HCRTR2KCNH2LTC4S
SCHEMBL24253544 0.86 HCRTR1 (0.31) HCRTR1HCRTR2KCNH2LTC4S
SCHEMBL30424528 0.86 FFAR4 (0.34) HCRTR1HCRTR2KCNH2LTC4SSLC6A2
SCHEMBL24253953 0.86 FFAR4 (0.34) HCRTR1HCRTR2KCNH2LTC4SSLC6A2
SCHEMBL24253947 0.85 HCRTR1 (0.39) HCRTR1HCRTR2KCNH2LTC4SSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
CN-116157404-A Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof 诺华股份有限公司 2023-05-23 CN disclosed
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof REN, NR3C2, PKD1 HCRTR1 2245/4885HCRTR2 3027/4885KCNH2 282/4885
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, NR3C2, PKD1 HCRTR1 2245/4885HCRTR2 3027/4885KCNH2 282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.